MedTrace Logo

The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma

NCT07314255 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-01-02

No results posted yet for this study

Summary

Clinincal data and pathological specimens from patients who had undergone at least one radioactive iodine-131 (\^131I) therapy in the Department of Nuclear Medicine at Jiangxi Cancer Hospital over the past 8-10 years were retrospectively collected (approximately 30-50 cases each in the \^131I treatment-responsive group vs. the \^131I treatment-resistant group). Patients in the \^131I treatment-resistant group underwent \^18F-Trop2 PET-CT imaging.

Inclusion criteria:

1. History of total thyroidectomy with postoperative pathology confirming papillary thyroid carcinoma (PTC);
2. At least one course of \^131I internal radiotherapy.

Exclusion criteria:

1. Presence of other severe comorbidities;
2. Incomplete clinical or follow-up data. The clinicopathological characteristics and Trop2 expression levels in tissue samples were compared between the \^131I treatment-responsive group and the \^131I treatment-resistant group.

Within the \^131I treatment-resistant group, comparisons were made between the rapidly progressing subgroup and the stable-disease subgroup under TSH-suppressive therapy in terms of clinicopathological features, tissue Trop2 expression levels, and SUVmax of metastatic lesions on \^18F-Trop2 PET-CT imaging. Factors influencing progression-free survival and overall survival in \^131I-resistant patients were analyzed.

Conditions

  • PTC
  • I-131
  • Trop2

Interventions

RADIATION

radioiodine-131 therapy

surgery, tsh inhibition therapy

Sponsors & Collaborators

  • Lin Zhou

    collaborator UNKNOWN

  • Zhijun Chen

    collaborator UNKNOWN

  • Yu Su

    collaborator UNKNOWN

  • Jingxiu Zhong

    collaborator UNKNOWN

  • Tianzhu Lu

    collaborator UNKNOWN

  • Jiangxi Provincial Cancer Hospital

    lead OTHER

Principal Investigators

  • lin zhou · Jiangxi Provincial Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-18
Primary Completion
2027-06-10
Completion
2027-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07314255 on ClinicalTrials.gov